H.C. Wainwright analyst Brandon Folkes assumed coverage of Milestone Pharmaceuticals (MIST) with a Buy rating and $5 price target Milestone is developing Cardamyst for the treatment of paroxysmal supraventricular tachycardia, the analyst tells investors in a research note. The firm sees a path to resubmission in 2025, and a 2026 approval. The company’s current enterprise value of $75M, ascribes a lower probability of resolving the complete response letter than is warranted, contends H.C. Wainwright.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST: